{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T06:15:03Z","timestamp":1759990503327},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":1384,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1016\/j.jhep.2009.04.019","type":"journal-article","created":{"date-parts":[[2009,5,29]],"date-time":"2009-05-29T16:59:07Z","timestamp":1243616347000},"page":"829-834","source":"Crossref","is-referenced-by-count":51,"title":["Clevudine myopathy in patients with chronic hepatitis B"],"prefix":"10.1016","volume":"51","author":[{"given":"Byung Kook","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeeyoung","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"So Young","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Hyeok","family":"Choe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soon Young","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoung Hoon","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Ho","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"So Dug","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang Hong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2009.04.019_bib1","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1128\/AAC.39.4.979","article-title":"Use of 2\u2019-fluoro-5-methyl-beta-l-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus","volume":"39","author":"Chu","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2009.04.019_bib2","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1128\/AAC.40.2.380","article-title":"Inhibition of hepatitis B virus by a novel l-nucleoside, 2\u2019-fluoro-5-methyl-beta-l-arabinofuranosyl uracil","volume":"40","author":"Pai","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2009.04.019_bib3","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1053\/jhep.2001.20899","article-title":"Antiviral activity of clevudine l-FMAU, (1-(2-fluoro-5-methyl-beta, l-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax)","volume":"33","author":"Peek","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2009.04.019_bib4","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.2165\/00003495-200565110-00001","article-title":"Drugs in development for hepatitis B","volume":"65","author":"Buti","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.jhep.2009.04.019_bib5","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJM199510263331702","article-title":"Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B","volume":"333","author":"McKenzie","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2009.04.019_bib6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000134943","article-title":"Mechanisms of zidovudine-induced mitochondrial toxicity and myopathy","volume":"82","author":"Scruggs","year":"2008","journal-title":"Pharmacology"},{"key":"10.1016\/j.jhep.2009.04.019_bib7","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1073\/pnas.93.8.3592","article-title":"Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts","volume":"93","author":"Lewis","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jhep.2009.04.019_bib8","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/hep.20257","article-title":"A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B","volume":"40","author":"Marcellin","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2009.04.019_bib9","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/hep.21166","article-title":"A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B","volume":"43","author":"Lee","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2009.04.019_bib10","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/hep.21629","article-title":"Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B","volume":"45","author":"Yoo","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2009.04.019_bib11","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1159\/000105442","article-title":"Clevudine therapy for 24 weeks further reduced serum hepatitis B virus DNA levels and increased ALT normalization rates without emergence of viral breakthrough than 12 weeks of clevudine therapy","volume":"50","author":"Lee","year":"2007","journal-title":"Intervirology"},{"key":"10.1016\/j.jhep.2009.04.019_bib12","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/hep.21800","article-title":"Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression","volume":"46","author":"Yoo","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2009.04.019_bib13","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1021\/jm960098l","article-title":"Structure\u2013activity relationships of 1-(2-deoxy-2-fluoro-beta-l-arabinofuranosyluracil) pyrimidine nucleosides as anti-hepatitis B virus agents","volume":"39","author":"Ma","year":"1996","journal-title":"J Med Chem"},{"key":"10.1016\/j.jhep.2009.04.019_bib14","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1517\/13543780802535760","article-title":"Clevudine: a promising therapy for the treatment of chronic hepatitis B","volume":"17","author":"Asselah","year":"2008","journal-title":"Exp Opin Invest Drugs"},{"key":"10.1016\/j.jhep.2009.04.019_bib15","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00002018-200023060-00001","article-title":"Toxicity of antiretroviral nucleoside and nucleotide analogues: is mitochondrial toxicity the only mechanism?","volume":"23","author":"Moyle","year":"2000","journal-title":"Drug Saf"},{"key":"10.1016\/j.jhep.2009.04.019_bib16","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1590\/S0004-282X2007000100018","article-title":"Toxic myopathies: muscle biopsy features","volume":"65","author":"Scola","year":"2007","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.jhep.2009.04.019_bib17","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1016\/j.clinthera.2007.12.032","article-title":"Telbivudine for the management of chronic hepatitis B virus infection","volume":"29","author":"Matthews","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.jhep.2009.04.019_bib18","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.3748\/wjg.14.3549","article-title":"Clinical features of adverse reactions associated with telbivudine","volume":"14","author":"Zhang","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2009.04.019_bib19","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0022-510X(99)00126-4","article-title":"Zidovudine-induced experimental myopathy: dual mechanism of mitochondrial damage","volume":"166","author":"Masini","year":"1999","journal-title":"J Neurol Sci"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827809003109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827809003109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T12:44:15Z","timestamp":1558356255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827809003109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["S0168827809003109"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2009.04.019","relation":{},"ISSN":["0168-8278"],"issn-type":[{"type":"print","value":"0168-8278"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}